Welcome to our dedicated page for Caris Life Sciences SEC filings (Ticker: CAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caris Life Sciences, Inc. filings document financial results, governance matters, financing arrangements and material company events for an AI TechBio precision medicine business. Form 8-K disclosures report quarterly and annual operating results, molecular profiling services revenue, clinical therapy selection activity, and Regulation FD updates tied to company presentations and diagnostic-development programs.
The company’s SEC record also includes a definitive proxy statement covering annual meeting proposals, director elections and auditor ratification. Other material-event filings describe senior secured credit facilities with subsidiary guarantees, amendments to bylaws affecting shareholder derivative proceedings, and capital-structure terms relevant to Caris’ public-company reporting obligations.
Caris Life Sciences executive John Russel Denton reported routine equity compensation activity. On May 15, 2026, 6,047 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, a non‑market tax-withholding disposition coded "F".
Following this event, Denton directly held 181,515 shares of common stock and indirectly held 9,184 shares through a trust. The filing shows no open-market purchases or sales, indicating a compensation-related adjustment rather than a discretionary trade.
Caris Life Sciences executive Luke Thomas Power used company stock to cover taxes on vested RSUs. On this Form 4, 9,771 shares of Common Stock were withheld at $15.25 per share to pay withholding taxes. After this tax-withholding disposition, he directly holds 153,771 shares.
Caris Life Sciences, Inc. president David Baxley Spetzler reported a routine tax-withholding disposition related to vested RSUs. On the transaction date, 13,856 shares of common stock were withheld at $15.25 per share to cover taxes, leaving him with 530,083 shares owned directly after the transaction.
Caris Life Sciences director Brian J. Brille reported routine equity compensation-related activity involving company common stock. On May 15, 2026, 13,987 shares of common stock were withheld at $15.25 per share to cover taxes on the vesting and settlement of RSUs, which is a tax-withholding disposition rather than an open-market sale.
After this tax withholding, Brille directly held 230,303 shares of common stock. In addition, a family trust held 500,000 shares of common stock, reflecting indirect ownership after previously separate family trusts were consolidated into a single trust. Brille disclaims beneficial ownership of these trust-held shares except to the extent of his pecuniary interest.
Caris Life Sciences director and major holder David D. Halbert reported a routine share disposition tied to equity compensation. On the vesting and settlement of restricted stock units (RSUs), 40,712 shares of Common Stock were withheld at $15.25 per share to cover tax obligations, which is recorded as a tax-withholding disposition rather than an open-market sale.
After this event, Mr. Halbert directly holds 2,574,533 shares of Common Stock. In addition, entities associated with him collectively hold 121,025,002 shares indirectly, including interests in Caris Halbert, L.P., ADAPT I Ltd., Carisome I, L.P., Caris Investment II Ltd., Caris Investment III Ltd., and Halbert Family Capital, LLC, with Mr. Halbert disclaiming beneficial ownership except to the extent of his pecuniary interest.
CARIS LIFE SCIENCES, INC. Schedule 13G/A (Amendment No. 2) discloses joint reporting by TSSP Sub-Fund HoldCo, LLC and Alan Waxman regarding beneficial ownership of Common Stock. As of March 31, 2026, the filing bases percentages on 282,579,919 shares outstanding as of February 26, 2026.
The cover data show Sub-Fund HoldCo with 13,666,128 shares (listed shared voting and dispositive power) representing 4.8% and Alan Waxman with 14,385,399 shares (listed shared voting and dispositive power) representing 5.1%. The filing describes layers of entity ownership and management relationships and includes joint filing and authorization exhibits.
Caris Life Sciences, Inc. (CAI) ownership update: J.H. Whitney VI, L.P. and affiliated reporting persons state beneficial ownership of 18,256,615 shares of common stock, representing 6.5% of the class. The filing attributes shared voting and dispositive power over those shares to the reporting entities.
The statement lists J.H. Whitney Equity Partners VI, LLC as the sole general partner and names Paul R. Vigano and Robert M. Williams Jr. as managing members; no other person is reported to have rights to dividends or sale proceeds.
Caris Life Sciences director Jeff L. Vacirca purchased 31,050 shares of Common Stock in an open-market transaction. The weighted average purchase price was $16.149 per share, with individual trade prices ranging from $16.13 to $16.15. Following this purchase, he directly owns 49,671 shares.
Caris Life Sciences reported strong Q1 2026 growth with total revenue of $216.174 million, up from $120.915 million a year earlier, driven mainly by molecular profiling services. The company generated income from operations of $5.282 million versus a prior operating loss and kept net loss nearly flat at $0.510 million.
Adjusted EBITDA improved to $26.2 million, and free cash flow turned positive at $22.5 million. Caris ended the quarter with $825.705 million in cash, cash equivalents, restricted cash and marketable securities and had $400.0 million of term loan debt outstanding before refinancing after quarter-end.
Caris Life Sciences reported a strong first quarter of 2026 as revenue and profitability metrics improved sharply. Total revenue reached $216.2 million, up 79% from the prior-year quarter, driven by $210.8 million in molecular profiling services revenue, which grew 85%. The company completed about 52,800 clinical therapy selection cases, a 15% increase, and delivered a gross margin of 65%, up from 47%.
Operating income was positive and net loss narrowed to just $0.5 million, with Adjusted EBITDA of $26.2 million. Cash generation improved markedly: operating cash flow was $32.9 million and free cash flow was $22.5 million, even after $30.5 million in annual bonus payments. Management reaffirmed 2026 revenue guidance of $1.0–$1.02 billion, implying 23%–26% growth over 2025, and about 20% clinical therapy selection volume growth.